Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

A project to pick up undiagnosed COPD in people who had attended lung health checks found 70% had the condition.

Health experts have warned that turning on the central heating can make respiratory and sinus conditions worse as it causes ...

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in ...

Grace Anne Dorney Koppel was told she only had a few years left after her 2001 COPD diagnosis. Now, the couple provides the ...

The scheme between Chiesi and Health Innovation Manchester is designed to catch lung exacerbations earlier with the goal of ...

Software is being rolled out to 150 GP practices across Greater Manchester with the aim of supporting better adult asthma and COPD care.

The research highlights how some chronic conditions, such as chronic obstructive pulmonary disease (COPD) and asthma, can ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

“Central heating dries up the air in the room. This can exacerbate certain lung conditions like asthma and chronic ...

The gas exchange pulmonary function testing market is expected to grow at a CAGR of 6.0% during the forecast period of 2024 to 2032. Gas exchange pulmonary fun ...